{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:47:09Z","timestamp":1761821229772,"version":"3.44.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.jneuroim.2007.11.020","type":"journal-article","created":{"date-parts":[[2008,2,22]],"date-time":"2008-02-22T11:46:19Z","timestamp":1203680779000},"page":"89-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis"],"prefix":"10.1016","volume":"194","author":[{"given":"Sara","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tali","family":"Feferman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Meidler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raanan","family":"Margalit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Sicsic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Yun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talma","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orgad","family":"Laub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam C.","family":"Souroujon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2007.11.020_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/jaut.2000.0433","article-title":"Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins","volume":"15","author":"Achiron","year":"2000","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0019-2791(77)90291-9","article-title":"Immunochemical studies on acetylcholine receptor from Torpedo californica","volume":"14","author":"Aharonov","year":"1977","journal-title":"Immunochemistry"},{"key":"10.1016\/j.jneuroim.2007.11.020_bib3","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.intimp.2005.11.013","article-title":"Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms","volume":"6","author":"Bayary","year":"2006","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncprheum0481","article-title":"Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action","volume":"3","author":"Bayry","year":"2007","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","article-title":"Intravenous immunoglobulins neutralize blocking antibodies in Guillain\u2013Barre syndrome","volume":"51","author":"Buchwald","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.20269","article-title":"Presynaptic effects of immunoglobulin G from patients with Lambert\u2013Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins","volume":"31","author":"Buchwald","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2007.11.020_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2141.1984.tb01266.x","article-title":"The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease","volume":"56","author":"Bussel","year":"1984","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacol. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.jneuroim.2007.11.020_bib9","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1007\/s100720200014","article-title":"High-dose intravenous immunoglobulin treatment of multiple sclerosis","volume":"23","author":"Durelli","year":"2002","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/jnnp.57.Suppl.55","article-title":"Experience with intravenous immunoglobulin in myasthenia gravis: a review","volume":"57","author":"Edan","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2007.11.020_bib11","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(84)92294-3","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Fateh-Moghadam","year":"1984","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.jneuroim.2007.11.020_bib12","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s100720200011","article-title":"High-dose intravenous immunoglobulin G treatment of myasthenia gravis","volume":"23","author":"Ferrero","year":"2002","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(84)90469-0","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Gajdos","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2007.11.020_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","article-title":"Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues","volume":"3","author":"Gold","year":"2007","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1469-7580.2002.00041.x","article-title":"Systematic reviews of treatment for inflammatory demyelinating neuropathy","volume":"200","author":"Hughes","year":"2002","journal-title":"J. Anat."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib17","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1172\/JCI8121","article-title":"Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment","volume":"104","author":"Im","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib18","first-page":"1096","article-title":"Treatment of rats with experimental allergic neuritis using high dose immunoglobulin","volume":"113","author":"Jia","year":"2000","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jneuroim.2007.11.020_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jns.2005.03.005","article-title":"Intravenous immunonoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis","volume":"233","author":"Jorgensen","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2007.11.020_bib21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.molimm.2004.07.046","article-title":"Therapeutic intravenous immunoglobulins","volume":"42","author":"Lemieux","year":"2005","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib23","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.4049\/jimmunol.146.7.2245","article-title":"Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis","volume":"146","author":"Lennon","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib24","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/(SICI)1521-4141(199806)28:06<1823::AID-IMMU1823>3.0.CO;2-F","article-title":"Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein","volume":"28","author":"Pashov","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/rheumatology\/41.4.367","article-title":"The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases","volume":"41","author":"Pyne","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jneuroim.2007.11.020_bib26","first-page":"713","article-title":"Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases","volume":"3","author":"Rutter","year":"2002","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.jneuroim.2007.11.020_bib27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2007.11.020_bib28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/intimm\/5.12.1559","article-title":"Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis","volume":"5","author":"Saoudi","year":"1993","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxf099","article-title":"Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus","volume":"14","author":"Shoenfeld","year":"2002","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0165-2478(85)90058-6","article-title":"Analysis and modulation of the immune response of mice to acetylcholine receptor by anti-idiotypes","volume":"9","author":"Souroujon","year":"1985","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1749-6632.1986.tb20858.x","article-title":"Idiotypes and anti-idiotypes in experimental autoimmune myasthenia gravis","volume":"475","author":"Souroujon","year":"1986","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib32","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/(SICI)1521-4141(199908)29:08<2436::AID-IMMU2436>3.0.CO;2-9","article-title":"Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice","volume":"29","author":"Vassilev","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1365-2249.2001.01499.x","article-title":"Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition","volume":"124","author":"Wada","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2007.11.020_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00401-002-0568-y","article-title":"Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis","volume":"104","author":"Weishaupt","year":"2002","journal-title":"Acta Neuropathol. (Berl)"},{"key":"10.1016\/j.jneuroim.2007.11.020_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jneuroim.2006.04.011","article-title":"Intravenous immunoglobulin suppresses experimental myasthenia gravis: Immunological mechanisms","volume":"176","author":"Zhu","year":"2006","journal-title":"J. Neuroimmunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572807004365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572807004365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:11:57Z","timestamp":1759047117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572807004365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":35,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0165572807004365"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2007.11.020","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2008,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2007.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}